02696.HK
Shanghai Henlius Biotech, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 49.06
−1.72%Year over year
Reported trailing growth
- Revenue
- +28.2%
- EBITDA
- +8.2%
- EBIT
- +5.7%
- EPS
- +4.6%
- Free cash flow
- -58.1%
- Operating cash flow
- -53.8%
Forward estimates
Based on analyst estimates
- Revenue
- +87.4%
- EBITDA
- +102.3%
- EPS
- +54.0%
Three-year CAGR
- Revenue
- +27.5%
- EBITDA
- +12.2%
- EBIT
- +13.7%
- Net income
- +21.5%
- EPS
- +21.2%
- Free cash flow
- +385.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026